Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Increased cortisol levels and genetic polymorphisms have been related to both major depressive disorder and antidepressant treatment outcome. The aim of this study is to evaluate the relationship between circadian salivary cortisol levels, cortisol suppression by dexamethasone and genetic polymorphisms in some HPA axis-related genes to the response to placebo and fluoxetine in depressed patients. METHODS: The diagnosis and severity of depression were performed using the Mini International Neuropsychiatric Interview (M.I.N.I.) and Hamilton depression scale (HAM-D17), respectively. Euthyroid patients were treated with placebo (one week) followed by fluoxetine (20 mg) (two months). Severity of depression was re-evaluated after placebo, three weeks and two months of fluoxetine treatments. Placebo response was defined as HAM-D17 score reductions of at least 25% and to < 15. Early response and response were reductions of at least 50% after three weeks and two months, and remission with ≤ 7 after two months. Plasma TSH, free-T4, circadian salivary cortisol levels and cortisol suppression by dexamethasone were evaluated. Seven genetic polymorphisms located in the Corticotrophin-releasing-hormone-receptor-1 (rs242939, rs242941, rs1876828), Corticotrophin-releasing-hormone-receptor-2 (rs2270007), Glucocorticoid-receptor (rs41423247), FK506-binding-protein-5 (rs1360780), and Arginine-vasopressin (rs3729965) genes were determined. Association analyses between response to placebo/fluoxetine and polymorphism were performed by chi-square or Fisher exact test. Cortisol levels were compared by t-test, ANOVA and the general linear model for repeated measures. RESULTS: 208 depressed patients were recruited, 187 of whom were euthyroid. Placebo responders, fluoxetine responders and remitters exhibited significantly lower circadian cortisol levels than those who did not respond (p-values of 0.014, 0.008 and 0.021 respectively). Patients who abandoned treatment before the third week also exhibited a trend to low cortisol levels (p = 0.057). The polymorphisms rs242939 (CRHR1) and rs2270007 (CRHR2) were not in Hardy-Weinberg equilibrium. Only the rs242939 polymorphism (CRHR1) exhibited association with early response (three weeks) to fluoxetine (p-value = 0.043). No other association between outcomes and polymorphisms was observed. CONCLUSIONS: These results support the clinical relevance of low salivary cortisol levels as a predictor of antidepressant response, either to placebo or to fluoxetine. Only one polymorphism in the CRHR1 gene was associated with the early response. Other factors may be involved in antidepressant response, although further studies are needed to identify them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salivary cortisol in psychoneuroendocrine research: recent developments and applications
Kirschbaum, C., & Hellhammer, D. H. (1994) · Psychoneuroendocrinology · doi:10.1016/0306-4530(94)90013-2 · Cited by 2,107 · cited 2×
“This increase only affects bound cortisol; free cortisol levels are unaltered in states of increased CBG [56].”
The epidemiology of thyroid disease
Vanderpump, M. P. J. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr030 · Cited by 1,179
Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 1×
“Non-suppression of cortisol secretion by dexametasone has been reported in depressed patients, supposedly caused by altered cortisol feedback inhibition [57].”
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“For antidepressant treatments, reduction in rating scales either for placebo or different antidepressants is perceived in the first week, however most placebo antidepressant effects are observed after 2–3 weeks [35,45-47].”
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977
Benedetti, F., Pollo, A., Lopiano, L., Lanotte, M., Vighetti, S., & Rainero, I. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-10-04315.2003 · Cited by 788 · cited 2×
“was observed in studies of placebo effects in analgesia, with the report of reduction of cortisol levels after placebo administration when preconditioned with sumatripan (a 5-HT1B/1D agonist that stimulates GH and inhibits cortisol secretion) [49].”
Enhanced memory for emotional material following stress-level cortisol treatment in humans
Buchanan, T. W., & Lovallo, W. R. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(00)00058-5 · Cited by 762
Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1243 · Cited by 721
Research and treatment approaches to depression
Wong, M.-L., & Licinio, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072566 · Cited by 656 · cited 1×
“Intriguingly, the therapeutic response is observed with a delay of several weeks after the initiation of treatment [7].”
The glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592 · cited 1×
“The most common antidepressants currently available, including fluoxetine (FLX), are targeted to the monoaminergic systems [5,6].”
Cited by
The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Abnormal stress responsiveness and suicidal behavior: a risk phenotype
Steinberg, L. J., & Mann, J. J. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100011 · Cited by 29
Metadata
- Authors
- Ventura-Juncá, R., Symon, A., López, P., Fiedler, J. L., Rojas, G., Heskia, C., Lara, P., Marín, F., Guajardo, V., Araya, A. V., Sasso, J., & Herrera, L.
- Venue
- BMC Psychiatry
- Published
- 2014-08-03
- Volume
- 14
- Issue
- 1
- Pages
- 220-220
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1990677889
- Cited by
- 34
- References
- 16
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study. https://app.cochat.ai/papers/10.1186/s12888-014-0220-0
- The paper
- Ventura-Juncá, R., Symon, A., López, P., Fiedler, J. L., Rojas, G., Heskia, C., Lara, P., Marín, F., Guajardo, V., Araya, A. V., Sasso, J., & Herrera, L. (2014). Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study. BMC Psychiatry. https://doi.org/10.1186/s12888-014-0220-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.